Chemotherapy for trophoblastic disease: Current standards

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 1, 2002, Pages 33-38

  Kendall, Anne ^a   Gillmore, Roopinder ^b   Newlands, Edward ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PACLITAXEL; VINCRISTINE;

ALOPECIA; ANEMIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHORIOCARCINOMA; CURETTAGE; FEMALE; GONADOTROPIN BLOOD LEVEL; HUMAN; HYDATIDIFORM MOLE; LONG TERM CARE; METASTASIS; NEUTROPENIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; STANDARD; THROMBOCYTOPENIA; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LEUCOVORIN; METHOTREXATE; NEOPLASM STAGING; PREGNANCY; PROGNOSIS; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS; VINCRISTINE;

EID: 0036182446     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200202000-00006     Document Type: Review

References (13)

1. Gestational trophoblastic disease: A study of mode of evacuation and subsequent need for treatment with chemotherapy
2. Treatment of gestational trophoblastic disease
3. Treatment of metastatic trophoblastic disease: Good and poor prognosis
4. Risk and prognostic factors in trophoblastic neoplasia
5. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment
6. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease
7. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease: Remission rates and drug toxicities
8. Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease
9. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
10. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors
11. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors
12. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors
13. Recent advances in gestational trophoblastic disease